Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment 5. Debunking Myths in the US Healthcare System
Top Ten Searches
aldosteronism contrast dialysis vitamin d bicarbonate arf amyloidosis hypocalcemia renal artery husYour Article Summary
See Latest ArticlesAdherence to Antihypertensive Medications: A Review and Update
High Blood Pressure & Cardiovascular Prevention, 09/18/09
Costa FV et al. – Some strong messages emerged: non–adherent patients have higher blood pressure (BP) values, which lead to a higher risk of cardiovascular events; angiotensin II type 1 receptor antagonists (angiotensin receptor blockers) are the AHTs with the best patient adherence and persistence to treatment; better treatment adherence is observed in patients using fixed versus extemporaneous AHT combinations. Improving BP control is pivotal to reduce cardiovascular events, allowing for a better use of healthcare resources, and good adherence and persistence to treatment are essential for reaching this goal.
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/20/09
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension
Journal of Human Hypertension, 11/10/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Kidney International, 11/05/09
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
Article Search
Sponsor